World News

The agreement brings together Lilly’s expertise in developing innovative medicines with Abu Dhabi’s advanced healthcare infrastructure, population-scale health data, and genomics capabilities.

The initiative has strengthened disease prevention, maternal healthcare services, laboratory capacity, and surveillance systems, helping the territory maintain high standards of care.

The new site will serve as the company’s U.S. global headquarters and future manufacturing centre as it accelerates the development of targeted cancer therapies.

Unlike conventional sequencing technologies, Axelios 1 uses SBX chemistry to convert DNA or RNA molecules into enlarged surrogate polymers known as Xpandomers.

Biogen has paused or discontinued funding for most of Apellis’ legacy research portfolio while conducting a comprehensive review of the acquired company’s clinical and preclinical assets.

BrightHeart will officially introduce the platform to European clinicians during the Fetal Medicine Foundation (FMF) World Congress in Vienna, taking place from June 28 to July 2, 2026.

Developed by Geneoscopy and offered commercially through Labcorp, ColoSense is intended for adults aged 45 to 85 years who are considered to have an average risk of colorectal cancer.

The acquisition gives Zymeworks access to Yupelri, an FDA-approved, once-daily nebulized maintenance therapy for chronic obstructive pulmonary disease (COPD) that Theravance markets in partnership with Viatris.

Ohana Specialist Hospital is a 30-bed private facility that specializes in paediatrics as well as obstetrics and gynaecology.

During the congress, specialists from the Moscow-based center presented research on head and neck imaging, the use of AI-powered diagnostic algorithms, and strategies for improving the quality of medical imaging examinations.